https://doi.org/10.1016/s0140-6736(18)31999-8
J
José Dinis
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
59
Papers
4.1K
Citations
16
h-index
21
i10-index
José Dinis is an academic researcher from Instituto Português de Oncologia Francisco Gentil. The author has contributed to research in topics: Head and Neck Cancer Studies & Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers. The author has an h-index of 16, co-authored 51 publications.
ORCID: 0000-0002-2684-8283Papers by this author
worksPembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
2018 · The Lancet · 1,656 citations
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
2018 · The Lancet · 1,656 citations
https://doi.org/10.1016/s0140-6736(18)31999-8
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
2023 · Oral Oncology · 11 citations
https://doi.org/10.1016/j.oraloncology.2023.106587
A New Era in Salivary Gland Carcinoma Treatment: A Case Report
2023 · Cureus · 1 citations
https://doi.org/10.7759/cureus.42983
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat